Latest Insider Transactions at Supernus Pharmaceuticals, Inc. (SUPN)
This section provides a real-time view of insider transactions for Supernus Pharmaceuticals, Inc. (SUPN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SUPERNUS PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SUPERNUS PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 22
2024
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
246
-0.28%
|
$6,642
$27.94 P/Share
|
|
Feb 22
2024
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
750
+0.86%
|
-
|
|
Feb 22
2024
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
500
+7.69%
|
-
|
|
Feb 22
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
335
-5.04%
|
$9,045
$27.94 P/Share
|
|
Feb 22
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Grant, award, or other acquisition
|
Direct |
750
+10.14%
|
-
|
|
Feb 22
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
372
-4.47%
|
$10,044
$27.94 P/Share
|
|
Feb 22
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
750
+8.26%
|
-
|
|
Feb 22
2024
|
Jonathan Rubin SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
303
-7.11%
|
$8,181
$27.94 P/Share
|
|
Feb 22
2024
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
750
+14.97%
|
-
|
|
Feb 12
2024
|
Jack A. Khattar President, CEO |
SELL
Other acquisition or disposition
|
Indirect |
16,500
-1.59%
|
-
|
|
Feb 12
2024
|
Jack A. Khattar President, CEO |
BUY
Other acquisition or disposition
|
Direct |
16,500
+1.81%
|
-
|
|
Jan 10
2024
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
8,000
-8.54%
|
$216,000
$27.91 P/Share
|
|
Jan 10
2024
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+7.87%
|
$72,000
$9.24 P/Share
|
|
Dec 22
2023
|
Jack A. Khattar President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,958
-1.34%
|
$322,866
$27.66 P/Share
|
|
Dec 22
2023
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+2.72%
|
-
|
|
Dec 22
2023
|
Jonathan Rubin SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
204
-5.92%
|
$5,508
$27.66 P/Share
|
|
Dec 22
2023
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+14.83%
|
-
|
|
Nov 16
2023
|
Charles W Newhall Iii Director |
SELL
Open market or private sale
|
Direct |
2,500
-2.09%
|
$70,000
$28.01 P/Share
|
|
Nov 16
2023
|
Charles W Newhall Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,457
+5.87%
|
$67,113
$9.24 P/Share
|
|
Nov 15
2023
|
Frederick M. Hudson Director |
SELL
Open market or private sale
|
Direct |
9,093
-11.36%
|
$254,604
$28.5 P/Share
|
|
Nov 15
2023
|
Frederick M. Hudson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,457
+14.98%
|
$67,113
$9.24 P/Share
|
|
Nov 14
2023
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Open market or private sale
|
Direct |
1,110
-16.35%
|
$31,080
$28.13 P/Share
|
|
Nov 14
2023
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+22.75%
|
$18,000
$9.24 P/Share
|
|
Oct 13
2023
|
Timothy C Dec Senior Vice-President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,911
-27.3%
|
$49,686
$26.91 P/Share
|
|
Oct 13
2023
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+36.36%
|
-
|
|
Sep 07
2023
|
Jack A. Khattar President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,804
-1.9%
|
$537,728
$32.1 P/Share
|
|
Sep 07
2023
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+3.81%
|
-
|
|
Sep 07
2023
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,182
-14.16%
|
$37,824
$32.1 P/Share
|
|
Sep 07
2023
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+23.05%
|
-
|
|
Aug 30
2023
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
8,100
-8.68%
|
$259,200
$32.0 P/Share
|
|
Aug 30
2023
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
8,100
+7.98%
|
$186,300
$23.99 P/Share
|
|
Aug 25
2023
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
5,135
-5.68%
|
$159,185
$31.59 P/Share
|
|
May 11
2023
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
750
+12.01%
|
-
|
|
May 11
2023
|
Jack A. Khattar President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,005
-1.74%
|
$540,180
$36.47 P/Share
|
|
May 11
2023
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+3.49%
|
-
|
|
May 11
2023
|
Timothy C Dec Senior Vice-President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
709
-21.11%
|
$25,524
$36.47 P/Share
|
|
May 11
2023
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+30.87%
|
-
|
|
Apr 11
2023
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
1,500
+24.01%
|
-
|
|
Mar 14
2023
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+2.34%
|
-
|
|
Mar 14
2023
|
Timothy C Dec Senior Vice-President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
789
-27.77%
|
$29,982
$38.65 P/Share
|
|
Mar 14
2023
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+34.55%
|
-
|
|
Mar 14
2023
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Open market or private sale
|
Direct |
4,780
-50.23%
|
$167,300
$35.99 P/Share
|
|
Feb 22
2023
|
Carrolee Barlow Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,882
+22.57%
|
-
|
|
Feb 22
2023
|
Frederick M. Hudson Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,882
+10.02%
|
-
|
|
Feb 22
2023
|
Georges Gemayel Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,882
+22.57%
|
-
|
|
Feb 22
2023
|
John M Siebert Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,882
+4.41%
|
-
|
|
Feb 22
2023
|
Charles W Newhall Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,882
+3.35%
|
-
|
|
Feb 22
2023
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Grant, award, or other acquisition
|
Direct |
750
+7.31%
|
-
|
|
Feb 22
2023
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
750
+0.82%
|
-
|
|
Feb 22
2023
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
500
+27.16%
|
-
|